Printed from https://ideas.repec.org/s/spr/eujhec8.html
Content
December 2010, Volume 11, Issue 6
- 525-531 The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration
by Kathleen Ke - 533-541 Adolescents alcohol-use and economic conditions: a multilevel analysis of data from a period with big economic changes
by Mikael Svensson & Curt Hagquist - 543-554 The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands
by Marcus Keogh-Brown & Richard Smith & John Edmunds & Philippe Beutels - 555-568 The effect of health care expenditure on sickness absence
by David Granlund - 569-584 The sustainability of public health expenditures: evidence from the Canadian federation
by Livio Di Matteo - 585-594 The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden
by Michael Willis & Marianne Svensson & Mickael Löthgren & Bo Eriksson & Anders Berntsson & Ulf Persson - 595-596 On the welfare theoretic foundation of CEA: comment
by Friedrich Breyer - 597-598 Cost-effectiveness analysis, welfare economics, and the societal perspective: a reply
by Bengt Liljas - 599-599 Erratum to: Hospital’s activity-based financing system and manager–physician interaction
by David Crainich & Hervé Leleu & Ana Mauleon
October 2010, Volume 11, Issue 5
- 435-435 EJHE has an official impact factor of 1.337
by J.-Matthias Graf von der Schulenburg - 437-447 Health insurance for the poor: impact on catastrophic and out-of-pocket health expenditures in Mexico
by Omar Galárraga & Sandra Sosa-Rubí & Aarón Salinas-Rodríguez & Sergio Sesma-Vázquez - 449-455 Expenditures of the German statutory health insurance system for patients suffering from acute coronary syndrome and treated with percutaneous coronary intervention
by Heiko Friedel & Anne Delges & Johannes Clouth & Dana Trautvetter - 457-469 Health impairments and labour market outcomes
by Nick Drydakis - 471-485 Onset of disability and life satisfaction: evidence from the German Socio-Economic Panel
by Ricardo Pagán-Rodríguez - 487-498 Health care utilisation and immigration in Spain
by José-Ignacio Antón & Rafael Muñoz de Bustillo - 499-511 Use of formal and informal care services among older people in Ireland and France
by Brenda Gannon & Bérengère Davin - 513-520 Spanish recommendations on economic evaluation of health technologies
by Julio López-Bastida & Juan Oliva & Fernando Antoñanzas & Anna García-Altés & Ramón Gisbert & Javier Mar & Jaume Puig-Junoy
August 2010, Volume 11, Issue 4
- 351-353 Feeding the economics of obesity in the EU in a healthy way
by Fernando Antonanzas & Roberto Rodríguez - 355-365 Optimal savings and health spending over the life cycle
by Tamara Fioroni - 367-381 The challenge of corporatisation: the experience of Portuguese public hospitals
by Guilhermina Rego & Rui Nunes & José Costa - 383-393 Geographic distribution of physicians in Portugal
by Correia Isabel & Veiga Paula - 383-393 Geographic distribution of physicians in Portugal
by Isabel Correia & Paula Veiga - 395-404 Substituting inpatient for outpatient care: what is the impact on hospital costs and efficiency?
by Kirsi Vitikainen & Miika Linna & Andrew Street - 405-412 Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain
by Juan Oliva-Moreno & Julio López-Bastida & Pedro Serrano-Aguilar & Lilisbeth Perestelo-Pérez - 413-418 Adverse selection in the health insurance market: some empirical evidence
by Marcelo Resende & Rodrigo Zeidan - 419-426 Modeling stroke management: a qualitative review of cost-effectiveness analyses
by Chantal Guilhaume & Delphine Saragoussi & John Cochran & Clément François & Mondher Toumi - 427-434 Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences
by Ralph Crott & Andrew Briggs
June 2010, Volume 11, Issue 3
- 235-238 Future challenges for health economics and health technology assessment of biological drugs
by László Gulácsi - 239-253 BMI and Spanish labour status: evidence by gender from the city of Barcelona
by Toni Mora - 255-266 The impact of missing data in the estimation of concentration index: a potential source of bias
by Hai Zhong - 267-277 The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany
by Tom Stargardt - 279-290 Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes
by Yi-Wen Tsai & Yu-Wen Wen & Weng-Foung Huang & Ken Kuo & Pei-Fen Chen & Hsin-Wei Shih & Yue-Chune Lee - 291-304 Principal agent relationships and the efficiency of hospitals
by Martijn Ludwig & Frits Merode & Wim Groot - 305-322 The welfare costs of HIV/AIDS in Eastern Europe: an empirical assessment using the economic value-of-life approach
by Julia Fimpel & Michael Stolpe - 323-330 Eliciting health state utilities from the general public for severe chronic pain
by S. Eldabe & A. Lloyd & L. Verdian & M. Meguro & G. Maclaine & S. Dewilde - 331-341 Copayments for ambulatory care in Germany: a natural experiment using a difference-in-difference approach
by Jonas Schreyögg & Markus Grabka - 343-350 The Irish ‘health basket’: a basket case?
by Samantha Smith
April 2010, Volume 11, Issue 2
- 117-118 US health care reform: a work in progress
by Sean Sullivan - 119-126 Inpatient length of stay: a finite mixture modeling analysis
by Chungkham Singh & Laishram Ladusingh - 127-140 In which ways do unhealthy people older than 50 exit the labour market in France?
by Thomas Barnay - 141-150 The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population
by Dieter Tscheulin & Florian Drevs - 151-160 Interactions between cigarette and alcohol consumption in rural China
by Xiaohua Yu & David Abler - 161-175 Primary care delivery, risk pooling and economic efficiency
by Michael Leung - 177-184 Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study
by Lars Wilhelmsen & Lennart Welin & Anders Odén & Arne Björnberg - 185-193 Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study
by Greg Lissovoy & Kathy Fraeman & John Teerlink & John Mullahy & Jeff Salon & Raimund Sterz & Amy Durtschi & Robert Padley - 195-203 A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden
by Ulf Persson & Michael Willis & Knut Ödegaard - 205-213 A social preference valuations set for EQ-5D health states in Flanders, Belgium
by Irina Cleemput - 215-225 A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures
by John Brazier & Yaling Yang & Aki Tsuchiya & Donna Rowen - 227-233 Health insurance in Croatia: dynamics and politics of balancing revenues and expenditures
by Luka Voncina & Jenni Kehler & Tamas Evetovits & Mario Bagat
February 2010, Volume 11, Issue 1
- 1-3 HTA in Germany: very special and specific
by Wolfgang Greiner & J.-Matthias Schulenburg - 5-13 On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected
by Bengt Liljas - 15-25 Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach
by Jan Jürgensen & Wolfgang Arns & Bastian Haß - 27-34 Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study
by Feng Xie & Ngai-Nung Lo & Jean-Eric Tarride & Daria O’Reilly & Ron Goeree & Hin-Peng Lee - 35-44 Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective
by Montserrat Vera-Llonch & Ellen Dukes & Javier Rejas & Oleg Sofrygin & Marko Mychaskiw & Gerry Oster - 45-55 The added value of thorough economic evaluation of telemedicine networks
by Myriam Le Goff-Pronost & Claude Sicotte - 57-66 An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?
by Rachel Elliott & Helen Weatherly & Neil Hawkins & Gillian Cranny & Duncan Chambers & Lindsey Myers & Alison Eastwood & Mark Sculpher - 67-76 Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis
by Yogesh Punekar & Neil Hawkins - 77-94 Health costs in patients treated for depression, in patients with depressive symptoms treated for another chronic disorder, and in non-depressed patients: a two-year prospective cohort study in anthroposophic outpatient settings
by Harald Hamre & Claudia Witt & Anja Glockmann & Renatus Ziegler & Gunver Kienle & Stefan Willich & Helmut Kiene - 95-104 Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure
by Sonja Merkesdal & Timm Kirchhoff & Diane Wolka & Gunter Ladinek & Adrian Kielhorn & Andrea Rubbert-Roth - 105-115 Cost effectiveness of palivizumab in Spain: an analysis using observational data
by Mark Nuijten & Wolfgang Wittenberg
January 2010, Volume 10, Issue 1
- 1-3 The burden of colorectal cancer: prevention, treatment and quality of services
by Panos Kanavos & Willemien Schurer - 5-13 Colorectal cancer care in Denmark: status and dilemmas
by Karsten Vrangbaek & Mikkel Nielsen - 15-20 Colorectal cancer in France
by Karine Chevreul - 21-26 Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer
by J.-Matthias Schulenburg & Anne Prenzler & Willemien Schurer - 27-33 Colocteral cancer management and prevention policies in Greece
by Mary Geitona & Panos Kanavos - 35-40 The disease burden of colorectal cancer in Hungary
by Imre Boncz & Valentin Brodszky & Márta Péntek & István Ágoston & Zsolt Nagy & Krisztián Kárpáti & Ildikó Kriszbacher & Péter Fuszek & László Gulácsi - 41-49 Colorectal cancer in Italy: a review of current national and regional practice on screening and treatment
by Cristina Masseria - 51-56 The status of colorectal cancer care in the Netherlands: past, present and future
by Willemien Schurer - 57-63 Colorectal cancer management in Poland: current improvements and future challenges
by Jacek Ruszkowski - 65-73 Colorectal cancer in Portugal
by Carlos Pinto & Ana Paquete & Irene Pissarra - 75-83 The challenge of colorectal cancer prevention in Spain
by Julio Lopez-Bastida & Begoña Bellas-Beceiro & Enrique Quintero-Carrión - 85-90 Colorectal cancer management in the United Kingdom: current practice and challenges
by Willemien Schurer & Panos Kanavos - 91-98 Colorectal cancer in Russia
by Maria Avksentyeva - 99-105 Colorectal cancer in Turkey: current situation and challenges for the future
by Mehtap Tatar & Fahreddin Tatar - 107-114 Colorectal cancer in Mexico: should a middle income country invest in screening or in treatment?
by Emma Verastegui & Alejandro Mohar - 115-129 The dynamics of colorectal cancer management in 17 countries
by Panos Kanavos & Willemien Schurer
October 2009, Volume 10, Issue 4
- 357-359 Ten arguments for a societal perspective in the economic evaluation of medical innovations
by Bengt Jönsson - 361-369 The socioeconomic costs of mental illness in Spain
by Juan Oliva-Moreno & Julio López-Bastida & Angel Montejo-González & Rubén Osuna-Guerrero & Beatriz Duque-González - 371-388 Can Mediterranean diet really influence obesity? Evidence from propensity score matching
by Andreas Drichoutis & Panagiotis Lazaridis & Rodolfo Nayga - 389-397 Importance of sociodemographic and morbidity aspects in measuring health-related quality of life: performances of three tools
by Cecilia Quercioli & Gabriele Messina & Emanuela Barbini & Giovanni Carriero & Mara Fanì & Nicola Nante - 399-407 GPs as citizens’ agents: prescription behavior and altruism
by Kim Olsen & Dorte Gyrd-Hansen & Andreas Boegh & Sofie Hansen - 409-419 Estimating the cost related to surveillance of colorectal cancer in a French population
by Catherine Lejeune & Christine Binquet & Franck Bonnetain & Amel Mahboubi & Michal Abrahamowicz & Thierry Moreau & Maria Raikou & Laurent Bedenne & Catherine Quantin & Claire Bonithon-Kopp - 421-428 Perceived job security and sickness absence: a study on moral hazard
by Jahangir Khan & Clas Rehnberg - 429-436 The lack of theoretical support for using person trade-offs in QALY-type models
by Lars Østerdal - 437-453 Contractual design and PPPs for hospitals: lessons for the Portuguese model
by Pedro Barros & Xavier Martinez-Giralt - 455-465 Alcohol and labor supply: the case of Iceland
by Tinna Asgeirsdottir & Kerry McGeary - 467-474 Private expenditure and the role of private health insurance in Greece: status quo and future trends
by Olga Siskou & Daphne Kaitelidou & Charalampos Economou & Peter Kostagiolas & Lycourgos Liaropoulos
July 2009, Volume 10, Issue 3
- 239-242 Why the econometrician is in good spirits: a workshop through the looking glass
by Carl Lyttkens - 243-254 Exploring spatial patterns in general practice expenditure
by Mickael Bech & Jørgen Lauridsen - 255-265 Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study
by Douglas Taylor & Ankur Pandya & David Thompson & Paula Chu & Jennifer Graff & James Shepherd & Nanette Wenger & Heiner Greten & Rafael Carmena & Michael Drummond & Milton Weinstein - 267-273 Cost of skin cancer in England
by S. Morris & B. Cox & N. Bosanquet - 275-285 The economic costs of Group B Streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England
by Elizabeth-Ann Schroeder & Stavros Petrou & Gail Balfour & Oya Edamma & Paul Heath - 287-297 The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals
by Ansgar Resch & Michael Wilke & Christian Fink - 299-308 Hybrid risk adjustment for pharmaceutical benefits
by Manuel García-Goñi & Pere Ibern & José Inoriza - 309-321 Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach
by Bastian Haß & Juliane Lungershausen & Nadine Hertel & Barbara Poulsen Nautrup & Wioletta Kotowa & Hiltrud Liedgens - 323-328 Material versus social deprivation and health: a case study of an urban area
by Angela Testi & Enrico Ivaldi - 329-336 Modelling health expenditure at the household level in Greece
by Manos Matsaganis & Theodore Mitrakos & Panos Tsakloglou - 337-346 Total costs of injury from accidents in the home and during education, sports and leisure activities: estimates for Norway with assessment of uncertainty
by Knut Veisten & Åse Nossum & Juned Akhtar - 347-355 The economics of cochlear implant management in France: a multicentre analysis
by Laurent Molinier & Hélène Bocquet & Vanina Bongard & Bernard Fraysse
May 2009, Volume 10, Issue 2
- 121-123 Is there a “continental” view of health economics evaluation?
by Claude Pen - 125-133 Pesticides and farmer health in Nicaragua: a willingness-to-pay approach to evaluation
by Hildegard Garming & Hermann Waibel - 135-148 The income distributive implications of recent private health insurance policy reforms in Australia
by Alfons Palangkaraya & Jongsay Yong & Elizabeth Webster & Peter Dawkins - 149-155 International comparison of orthotic brace prices
by Steven Simoens & Paul Guillaume & Ingrid Moldenaers & Antony Depoorter & Sandra Coster & Dirk den Steen & Stefaan Sande & Hans Debruyne & Dirk Ramaekers & Murielle Lona - 157-165 Guidelines for completing the EURONHEED transferability information checklists
by John Nixon & Stephen Rice & Michael Drummond & Stephanie Boulenger & Philippe Ulmann & Gerard Pouvourville - 167-178 The labor supply of registered nurses in Finland: the effect of wages and working conditions
by T. Kankaanranta & P. Rissanen - 179-186 Patient characteristics and fairness
by Hannu Valtonen - 187-196 Can we assume that research participants are utility maximisers?
by Gethin Griffith & Val Morrison & J. Williams & Rhiannon Edwards - 197-206 Activity-based funding for National Health Service hospitals in England: managers’ experience and expectations
by Jonathan Sussex & Shelley Farrar - 207-215 Quality choice in a health care market: a mixed duopoly approach
by Yasuo Sanjo - 217-226 Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort
by Ulf-Göran Gerdtham & L. Andersson & Åsa Ericsson & Sixten Borg & Sven-Arne Jansson & Eva Rönmark & Bo Lundbäck - 227-231 Factors affecting nurses’ decision to get the flu vaccine
by Shosh Shahrabani & Uri Benzion & Gregory Yom Din - 233-236 Response to the expertise: Procedures and methods of benefit assessments for medicines in Germany, by Geertruida E. Bekkering and Jos Kleijnen
by Klaus Koch & Stefan Lange - 237-238 Procedures and methods of benefit assessments for medicines in Germany: give the child a name
by Holger Schünemann & Regina Kunz & Yngve Falck-Ytter & Nancy Santesso
February 2009, Volume 10, Issue 1
- 1-3 Can we afford to ignore missing data in cost-effectiveness analyses?
by Andrea Marshall & Lucinda Billingham & Stirling Bryan - 5-13 Health care costs, work productivity and activity impairment in non-malignant chronic pain patients
by Christian Kronborg & Gitte Handberg & Flemming Axelsen - 15-23 SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility
by Richard Grieve & Marina Grishchenko & John Cairns - 25-38 Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects
by Christa Claes & Ralf Reinert & Johann-Matthias Schulenburg - 39-45 Comparing methodologies for the cost estimation of hospital services
by S. Tan & F. Rutten & B. Ineveld & W. Redekop & L. Hakkaart-van Roijen - 47-55 Cost utility analysis of knee prosthesis with complete microprocessor control (C-leg) compared with mechanical technology in trans-femoral amputees
by Simone Gerzeli & Aleksandra Torbica & Giovanni Fattore - 57-63 The relationship between the Balanced Budget Act and length of stay for Medicare patients in US hospitals
by Mustafa Younis & Dana Forgione - 65-79 Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany
by Dirk Schürmann & Sonja Sorensen & Erwin Cock & Sandeep Duttagupta & Ansgar Resch - 81-91 A comparison between willingness to pay and willingness to give up time
by Debby Helvoort-Postulart & Carmen Dirksen & Alfons Kessels & Jos Engelshoven & M. Myriam Hunink - 93-101 The quality of life of Palestinians living in chronic conflict: assessment and determinants
by Awad Mataria & Rita Giacaman & Angelo Stefanini & Nirmala Naidoo & Paul Kowal & Somnath Chatterji - 103-109 Do quality-adjusted life years take account of lost income? Evidence from an Australian survey
by Jeff Richardson & Stuart Peacock & Angelo Iezzi - 111-119 An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event
by Manouchehr Tavakoli & Neil Pumford & Mark Woodward & Alex Doney & John Chalmers & Stephen MacMahon & Ronald MacWalter
November 2008, Volume 9, Issue 4
- 311-312 Health technology assessment: for whom the bell tolls?
by Livio Garattini & Gianluigi Casadei - 313-323 Decision-analytical modelling in health-care economic evaluations
by Xin Sun & Thomas Faunce - 325-331 Discarded cellular components and the technical efficiency of component preparation
by Marketta Veihola & Pekka Aroviita & Riitta Kekomäki & Miika Linna & Harri Sintonen - 333-342 Nurses’ intentions to leave nursing in Finland
by T. Kankaanranta & P. Rissanen - 343-349 Lessons for health care reform from the less developed world: the case of the Philippines
by Konrad Obermann & Matthew Jowett & Juanito Taleon & Melinda Mercado - 351-360 The societal cost of alcohol consumption: an estimation of the economic and human cost including health effects in Sweden, 2002
by Johan Jarl & Pia Johansson & Antonina Eriksson & Mimmi Eriksson & Ulf-G. Gerdtham & Örjan Hemström & Klara Selin & Leif Lenke & Mats Ramstedt & Robin Room - 361-367 Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France
by Laurence Clerc & Valérie Jooste & Catherine Lejeune & Bernard Schmitt & Patrick Arveux & Catherine Quantin & Jean Faivre & Anne-Marie Bouvier - 369-380 Health insurance theory: the case of the missing welfare gain
by John Nyman - 381-384 Economic evaluation of innovative technologies in health care should include a short-run perspective
by Eddy Adang - 385-392 Public funding for community-based skilled delivery care in Indonesia: to what extent are the poor benefiting?
by Tim Ensor & Mardiati Nadjib & Zahid Quayyum & Amila Megraini - 393-403 Expanding access to primary care without additional budgets? A case study from Burkina Faso
by Paul Marschall & Steffen Flessa - 405-416 Redistributive effects in public health care financing
by Ivonne Honekamp & Daniel Possenriede
August 2008, Volume 9, Issue 3
- 205-207 IQWiG: an opportunity lost?
by Bengt Jönsson - 209-219 Quality of life and cost-effectiveness of acupuncture treatment in patients with osteoarthritis pain
by Thomas Reinhold & Claudia Witt & Susanne Jena & Benno Brinkhaus & Stefan Willich - 221-228 Economic consequences of near-patient test results: the case of tests for the Helicobacter Pylori bacterium in dyspepsia
by Siri Fauli & Geir Thue - 229-236 The cost of treating high blood pressure in general practice in France
by Yaël Tibi-Levy & Gérard Pouvourville & Jérémie Westerloppe & Marion Bamberger - 237-249 An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions
by Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir - 251-259 Estimating the expected value of partial perfect information: a review of methods
by Doug Coyle & Jeremy Oakley - 261-264 Choice determinants of the mobility in the Dutch health insurance market
by Ilaria Mosca & Anoushka Schut-Welkzijn - 265-274 Predisposing factors for early retirement in patients with Schizophrenia in Germany
by Reinhard Schnabel & Heiko Friedel & Andreas Erfurth & Matthias Angermayer & Johannes Clouth & Florian Eichmann - 275-284 Preferences and utilities for the symptoms of moderate to severe allergic asthma
by Andrew Lloyd & Scott Doyle & Sarah Dewilde & Florian Turk - 285-292 In pursuit of QALY weights for relatives: empirical estimates in relatives caring for older people
by Thomas Davidson & Barbro Krevers & Lars-Åke Levin - 293-304 A theoretical and empirical investigation of nutritional label use
by Andreas Drichoutis & Panagiotis Lazaridis & Rodolfo Nayga & Maria Kapsokefalou & George Chryssochoidis - 305-310 Pricing and reimbursement of pharmaceuticals in Italy
by Pietro Folino-Gallo & Simona Montilla & Mario Bruzzone & Nello Martini
May 2008, Volume 9, Issue 2
- 99-101 The CHESME Health Economic Evaluations Database (CHESME HEED) project
by Dimitrios Rovithis & Lycurgus Liaropoulos - 103-115 Costing maternal health services in South Tanzania
by Claudia Both & Albrecht Jahn & Steffen Fleßa - 117-125 Primary physicians’ response to changes in fees
by Jostein Grytten & Fredrik Carlsen & Irene Skau - 127-136 The search for good compliance: economic aspects of a conveyed combination pharmaco-therapy, exemplified by an osteoporosis therapy
by Peter Oberender & Jürgen Zerth - 137-145 Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD
by Susan Griffin & Helen Weatherly & Gerry Richardson & Mike Drummond - 147-156 The role of non-need factors in individual GP utilisation analysis and their implications for the pursuance of equity: a cross-country comparison
by P. McGregor & P. McKee & C. O’Neill - 157-163 Eligibility for free GP care, “need” and GP visiting in Ireland
by A. Nolan & B. Nolan - 165-170 Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial
by Hans Janka & Barbara Högy - 171-183 Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
by Jonathan Karnon & Thomas Delea & Vicki Barghout - 185-191 The impact of generic substitution on price competition in Finland
by Ville Aalto-Setälä - 193-201 Spillover of cause-specific longevity interventions: an independent mortality risk model
by Liqun Liu - 203-203 Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance
by Barbara Högy & Heinz-Otto Keinecke & Michael Borte
November 2008, Volume 9, Issue 1
- 1-3 Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy
by Thomas Müller - 5-29 Procedures and methods of benefit assessments for medicines in Germany
by Geertruida Bekkering & Jos Kleijnen - 31-43 Biostatistical aspects for the use of evidence based medicine in health technology assessment
by Nick Freemantle
February 2008, Volume 9, Issue 1
- 1-6 Alcohol consumption in the EU: health economics and policy issues under a permanent debate
by Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Emilio Barco & Manuel Ramírez & Mariola Pinillos - 7-15 Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects
by Adam Lloyd & Nishma Patel & David Scott & Claus Runge & Christa Claes & Markus Rose - 17-22 Estimation and comparison of ostomy appliance costs with tariffs in Belgium
by Veerle Vanleene & Luc Maré & Ingrid Moldenaers & Hans Debruyne & Steven Simoens & Dirk Steen & Dirk Ramaekers - 23-32 Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia
by Ramon Sabes-Figuera & José Segú & Jaume Puig-Junoy & Antoni Torres - 33-39 Vaccination versus “wait and treat”: how to subsidize them?
by Louis Eeckhoudt & Maurice Marchand & Pierre Pestieau & Gwenaël Piaser - 41-50 The differences in characteristics between health-care users and non-users: implication for introducing community-based health insurance in Burkina Faso
by Hengjin Dong & Adjima Gbangou & Manuela Allegri & Subhash Pokhrel & Rainer Sauerborn - 51-61 Work environment satisfaction and employee health: panel evidence from Denmark, France and Spain, 1994–2001
by Nabanita Datta Gupta & Nicolai Kristensen - 63-67 Does greater exposure to own-health data make a difference on the visual analog scale?
by Amir Shmueli & David Messika & Havi Murad & Laurence Freedman - 69-78 Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone
by Jose-Luis Pinto-Prades & Veronica Farreras & Jaime de Bobadilla - 79-86 Factors influencing hospital costs of lung cancer patients in Northern Ireland
by Ian Fleming & Pauline Monaghan & Anna Gavin & Ciaran O’Neill - 87-97 Pharmaceutical pricing and reimbursement reforms in Greece
by John Yfantopoulos
January 2008, Volume 8, Issue 2
- 33-34 Patient access to rheumatoid arthritis treatments
by Bengt Jönsson & Gisela Kobelt & Josef Smolen - 35-38 Patient access to rheumatoid arthritis treatments
by Bengt Jönsson - 39-47 The burden of rheumatoid arthritis and access to treatment: a medical overview
by J. Smolen & D. Aletaha - 49-60 The burden of rheumatoid arthritis and access to treatment: health burden and costs
by J. Lundkvist & F. Kastäng & G. Kobelt - 61-86 The burden of rheumatoid arthritis and access to treatment: uptake of new therapies
by B. Jönsson & G. Kobelt & J. Smolen - 87-93 The burden of rheumatoid arthritis and access to treatment: determinants of access
by J. Lundqvist & F. Kastäng & G. Kobelt & B. Jönsson - 95-106 The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments
by G. Kobelt & B. Jönsson
December 2007, Volume 8, Issue 4
- 301-304 Tobacco policies in the European Union: a need for state and continental harmonisation?
by Fernando Antoñanzas & Roberto Rodríguez - 305-312 Foreign direct investment in the health care sector and most-favoured locations in developing countries
by J. Outreville - 313-323 Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery
by Jonas Lundkvist & David Bergqvist & Bengt Jönsson - 325-332 The impact of home hospitalization on healthcare costs of exacerbations in COPD patients
by Jaume Puig-Junoy & Alejandro Casas & Jaume Font-Planells & Joan Escarrabill & Carme Hernández & Jordi Alonso & Eva Farrero & Gemma Vilagut & Josep Roca - 333-337 Pricing matrix model: dealing with uncertainty
by Mark Nuijten - 339-346 The incidence and cost of cardiac surgery adverse events in Australian (Victorian) hospitals 2003–2004
by Jonathon Ehsani & Stephen Duckett & Terri Jackson - 347-357 Assessment of the pharmaceutical market in Poland after accession to the European Union
by Patricia Willert - 359-359 Costs and quality of life in multiple sclerosis in The Netherlands
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bert Anten & Mattias Ekman & Peter Jongen & Chris Polman & Bernard Uitdehaag
September 2007, Volume 8, Issue 3
- 179-179 Editor’s note
by J.-Matthias Graf von der Schulenburg & Wolfgang Greiner - 181-193 Innovation in hospitals: a survey of the literature
by Faridah Djellal & Faïz Gallouj - 195-212 Risk adjustment policy options for casemix funding: international lessons in financing reform
by Kathryn Antioch & Randall Ellis & Steve Gillett & Daniel Borovnicar & Ric Marshall - 213-223 Incorporating efficiency in hospital-capacity planning in Germany
by Ludwig Kuntz & Stefan Scholtes & Antonio Vera - 225-236 Variations in activity and practice patterns: a French study for GPs
by Sophie Béjean & Christine Peyron & Renaud Urbinelli - 237-243 Income-related health inequality in Belgium: a longitudinal perspective
by Ann Lecluyse - 245-251 Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners
by Ariel Berger & Piotr Kramarz & Gry Kopperud & John Edelsberg & Gerry Oster - 253-266 Patient access to pharmaceuticals: an international comparison
by Joshua Cohen & Laura Faden & Susan Predaris & Brian Young